SNX1 and ovarian cancer: These results suggest that SNX1 overexpression selectively enhances the sensitivity of ovarian cancer cells to paclitaxel but not to carboplatin, highlighting the need for further mechanistic studies to validate SNX1 as a biomarker for differential chemosensitivity in ovarian cancer.